Liver Injury Caused by Green Tea Extract in PD-1-/- Mice: An Impaired Immune Tolerance Model for Idiosyncratic Drug-Induced Liver Injury

被引:19
|
作者
Cho, Tiffany [1 ]
Wang, Xijin [1 ]
Yeung, Karen [2 ]
Cao, Yanshan [1 ]
Uetrecht, Jack [1 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 3M2, Canada
[2] Univ Toronto, Temerty Fac Med, Dept Immunol, Toronto, ON M5S 3M2, Canada
基金
加拿大健康研究院;
关键词
D O I
10.1021/acs.chemrestox.0c00485
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Idiosyncratic drug-induced liver injury (IDILI) is an idiosyncratic drug reaction that is specific to an individual and can lead to liver failure and even death. The mechanism of IDILI remains poorly understood, but most IDILI appears to be immune-mediated. We have developed the first validated animal model by using a PD-1(-/-) mouse model in combination with anti-CTLA-4 to block immune checkpoints and impair immune tolerance. Treatment of these mice with drugs that cause IDILI in humans led to delayed-onset liver injury with characteristics similar to IDILI in humans. The current study investigates the effects of green tea extract, a weight-loss dietary supplement that has been reported to cause IDILI in humans. Green tea extracts contain a highly variable content of catechins including (-)-epigallocatechin gallate, the major catechin in green tea formulations. If the liver injury caused by green tea extract in humans is immune-mediated, it may occur in our impaired immune tolerance model. Female PD-1(-/-) mice treated with anti-CTLA-4 antibody and green tea extract (500 mg/kg), a dose that is considered a no-observed-adverse-effect level for liver in rodents, produced a delayed onset increase in serum alanine transaminase levels and an increase in hepatic CD8(+) T cells. In contrast, the response in male PD-1(-/-) mice was less pronounced, and there was no evidence of liver injury in wild-type mice. These findings are consistent with the hypothesis that the IDILI caused by green tea extract is immune-mediated and is similar to IDILI caused by medications that are associated with IDILI.
引用
收藏
页码:849 / 856
页数:8
相关论文
共 50 条
  • [22] Treatment of Idiosyncratic Drug-Induced Liver Injury Using Steroids
    Sundaram, Suneha
    Vuppalanchi, Raj
    Saxena, Romil
    Chalasani, Naga
    ACG CASE REPORTS JOURNAL, 2020, 7 (02)
  • [23] Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges
    Jee, Alison
    Sernoskie, Samantha Christine
    Uetrecht, Jack
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (06) : 1 - 26
  • [24] Risankizumab-Associated Idiosyncratic Drug-Induced Liver Injury
    Jasti, Vivek V.
    Michaels, Anthony
    Govani, Shail
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S2744 - S2744
  • [25] Idiosyncratic drug-induced liver injury: an update on the 2007 overview
    Hussaini, S. Hyder
    Farrington, Elizabeth Anne
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (01) : 67 - 81
  • [26] Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury
    Roth, Robert A.
    Kana, Omar
    Filipovic, David
    Ganey, Patricia E.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2022, 18 (7-8) : 469 - 481
  • [27] In search of susceptibility factors for idiosyncratic drug-induced liver injury
    Reilly, TP
    DRUG METABOLISM REVIEWS, 2002, 34 : 44 - 44
  • [28] Epidemiology and Risk Factors for Idiosyncratic Drug-Induced Liver Injury
    Bjornsson, Einar S.
    SEMINARS IN LIVER DISEASE, 2014, 34 (02) : 115 - 122
  • [29] Topiramate as the Solitary Cause of Idiosyncratic Drug-Induced Liver Injury
    Green, John
    Idriss, Rajab
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S1181 - S1181